Ranked among the highest-rated Harvard Medical School CME courses, past participants consistently report that this program has inspired and improved their clinical practice and outcomes. Here are a few comments from recent attendees of this course:
Much of what I learned can be directly applied to treating patients.
Among the many bullet points I have taken from this phenomenal program: maximizing beta blockade in CHF clinic; more use of bisoprolol; improved assessment strategies in PVD; more end-of-life discussions with CHF and device patients.
This course has increased my confidence in engaging in end-of-life discussions, and in the assessment/management of pulmonary HTN and CVI.
After attending this course, my daily practice incudes wider introduction of NOACS with respect to atrial fibrillation and VTE, improved heart failure strategies, increased awareness of the impact of OSA in CVD, a better approach to PHT patients, updates in pericarditis management, re-evaluation of hypothermia protocols, and a new commitment to broaching end-of-life discussions with patients and caregivers.
This course has led to modifications in my approach to ACS with updating biomarkers and CCTA/Ca scoring.
To list just a few of the changes inspired by this course: I now have a better understanding of the pharmacology and clinical benefits of NOACs; I have updated my evaluation and Rx of pulmonary embolus with the incorporation of low-dose mechanical Rx of the pulmonary artery clot; greater awareness of cardiac oncology.
We have begun a quality improvement project to reduce CHF admissions at the ED level.
My practice has updated its use of platelet assays, its approach to STEMI/ NSTEMI treatment options and diagnosis, and the evaluation of surgical therapy.
The bench-to-bedside approach to teaching—pulling disease pathophysiology from cellular/biochemical level and expanding it to human case examples and to the public health sphere—was exceptional.
I have rethought ticagrelor and duration of DAPT.
I am increasing dose titration for beta-blockers in CHF.
To name a few of the ways this program has changed my practice: I am now using more NOACs and am more knowledgeable concerning the subselectivity of the class; I have updated my thinking about DVT and PE; and am instituting a "Code Aorta" program for my hospital.
The availability of the faculty to answer questions was truly remarkable.
I am now more comfortable with prescribing new oral anticoagulants to my elderly patients instead of Coumadin®.
This program convinced me to extend the duration of anti-platelet therapy, and I have new insight into prevention of heart failure prior to onset.
I use ticagrelor a lot more and Plavix® less, rule out people with troponins for less time, and am investigating the availability of catheter-based thrombolysis in PE in my facility.
I have started testing patients with CV risk factors for sleep apnea and CRP, possibly il-6; I also recommend that my patients get a pedometer.
Now I feel more comfortable in the use of NOCAs with atrial fibrillation and the other indications. I also think more about CTA in appropriate situations, and am utilizing the ideas presented in this course to start an outpatient heart failure clinic to decrease readmissions.
The information presented was exceptionally up to date.
This course inspired me to more aggressive anticoagulation of patients with atrial fibrillation; more aggressive use of triple therapy in patients with coronary artery disease and atrial fibrillation; and use of neprilysin inhibitors for systolic heart failure patients.
The clinical impact of this course on general practitioners from a specialist's point of view was very impressive and practical.
I have changed my management of CAD, AFIB, CHF and aortic disease due to this program.
The course presenters were superb, clearly knowledgeable, and dedicated to being present beyond the 1-2 hours surrounding his/her presentation.
I have become more likely to extend use of DAPT; more likely to consider catheter-based tPA in setting of submassive PE or ilian DVT; and I now extend use of NOACS post-DVT.
Recommending resistance exercise for patients as well as continuing advice on moderate aerobic exercise has become a part of my routine. I also now screen male smokers over 60 with vascular disease for abdominal aortic aneurysm.
This program changed the way I interpret angiotomography and nuclear exams.
I am more aggressive with sleep apnea and diabetes and statin therapy in my practice.
I have rethought my approach to venous stasis disease, and screen more for OSA in my Afib and heart failure patients.
I now use NOACs in the outpatient treatment of DVT from the beginning, and I order more sleep consults in patients with uncontrolled HTN.
There are so many ways my practice has been affected: more use of ticagrelor in ACS, more effective use of NOAC in VTE, more effective management of pericardial effusion, more evidence-based and efficient preop evals, more practical understanding of therapeutic hypothermia, more evidence-based approach to management of PFO and cryptogenic stroke, enhanced risk-profiling use of hsCRP.
I was very impressed by the high level of expert presenters and the solid evidence-based information they provided. I was also highly impressed by the comprehensive nature of the course, covering all aspects of cardiovascular care. Very current! It was fantastic and I will be back again.
The excellent speakers who are world leaders in the field made this course outstanding.